

1 Association between SARS-CoV-2 and Stroke: Perspectives from a metaumbrella-review.

2 Andreza Maria Luzia Baldo de Souza, Universidade Estadual de Campinas/ UNICAMP,
3 Faculdade de Odontologia de Piracicaba/FOP, departamento de Ciências da Saúde e
4 Odontologia Infantil, <https://orcid.org/0000-0002-6575-2209>

5
6 Enoque Fernandes de Araújo, Universidade Estadual de Campinas/ UNICAMP, Faculdade de
7 Odontologia de Piracicaba/FOP, departamento de Ciências da Saúde e Odontologia Infantil,
8 <https://orcid.org/0000-0003-3239-1467>

9
10 Nelson Carvas Junior, Universidade Paulista UNIP, <https://orcid.org/0000-0003-2168-8927>

11
12 Augusto César Raimundo, Universidade Estadual de Campinas/ UNICAMP, Faculdade de
13 Odontologia de Piracicaba/FOP, departamento de Ciências da Saúde e Odontologia Infantil,
14 <https://orcid.org/0000-0001-7736-9189>

15
16 Antonio Carlos Pereira, Universidade Estadual de Campinas/ UNICAMP, Faculdade de
17 Odontologia de Piracicaba/FOP, departamento de Ciências da Saúde e Odontologia Infantil
18 <https://orcid.org/0000-0003-1703-8171>

19
20 Marcelo de Castro Meneghim, Universidade Estadual de Campinas/ UNICAMP, Faculdade
21 de Odontologia de Piracicaba/FOP, departamento de Ciências da Saúde e Odontologia
22 Infantil, <https://orcid.org/0000-0003-2673-3627>

23
24
25 Address Avenida Limeira 901, Bairro Areião, CEP13414903, Piracicaba- SP, Brasil.
26 Corresponding author Andreza Maria Luzia Baldo de Souza E-mail: andrezamlb@gmail.com

27
28 Authors' contributions: AMLB Souza contributed to the conception and design, analysis and
29 interpretation of the data, writing of the article, and final approval of the version to be
30 published. EFA collaborated with the conception and design, writing of the article and
31 interpretation of the data. NCJ – analyses statistic, ACR collaborated with the conception and
32 design, writing of the article and interpretation of the data. AC Pereira contributed with a
33 relevant critical review of the intellectual content and final approval of the version to be
34 published. MCM contributed with a relevant critical review of the intellectual content and
35 final approval of the version to be published

36
37 Keywords- SARS-CoV-2, Stroke, Risk Factors, Metaumbrella, Systematic Review.

38
39 Word Count -5123

40
41 Figure 1- Prism

42 Figure 2 - Quality of the ROBIS studies.

43 Figure 3. Meta Umbrella showing the association between COVID-19 and stroke.

44 Figure 4. Matrix of overlapping studies in the systematic review.

45 Figure 5. Umbrella Goal stratified by Evidence Classification.

46 Table 1 - Total participants and P values from the Egger and JK test

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

47 Association between SARS-CoV-2 and Stroke: Perspectives from metaumbrella-review.

48 Abstract

49 In the face of the global COVID-19 pandemic, the need arose to investigate potential
50 complications associated with SARS-CoV-2, including the risk of Stroke. **Objective:** This
51 study aimed to verify the association between SARS-CoV-2 and the risk of Stroke, based on
52 systematic reviews and meta-analyses, in order to assess the inclusion of the virus as a new
53 risk factor for cerebrovascular diseases. **Methods:** A metaumbrella was conducted, which
54 included 34 systematic reviews, of which 4 were selected for the final analysis based on
55 methodological quality and consistency. The analysis aggregated the results of 70 primary
56 studies, considering different stroke subtypes and outcomes associated with COVID-19.
57 Study heterogeneity was assessed using the I^2 index, and significance bias was verified using
58 Egger's test. **Results:** The analysis showed that the severity of COVID-19 is significantly
59 associated with an increased risk of stroke (eOR = 2.48; 95%CI: 1.55 – 3.95), particularly for
60 ischemic stroke (eOR = 1.76; 95%CI: 1.11 – 2.80) and hemorrhagic stroke (eOR = 3.86;
61 95%CI: 1.79 – 8.33). Additionally, patients with cerebrovascular comorbidities had higher
62 mortality (eOR = 2.48; 95%CI: 2.48 – 19.63), as did those who had previously suffered a
63 stroke (eOR = 6.08; 95%CI: 3.73 – 9.91). **Conclusion:** The association between SARS-CoV-
64 2 and stroke was consistent and significant, suggesting that COVID-19 should be considered a
65 new risk factor for cerebrovascular diseases. However, the high heterogeneity among the
66 studies analyzed reinforces the need for further research to consolidate this relationship.

67 **Keywords:** SARS-CoV-2, Stroke, Risk Factors, Metaumbrella, Systematic Review.

68 Introduction

69 Responsible for millions of deaths annually, stroke is a global public health
70 challenge¹⁻³. It is a sudden neurological deficit, which can be transient or permanent, caused
71 by a vascular injury that results in ischemia or hemorrhage in areas of the brain². Stroke is a
72 multifactorial disease, caused by a combination of modifiable, non-modifiable, and
73 environmental risk factors^{1,4,5}.

74 The COVID-19 pandemic, caused by the SARS-CoV-2 virus, triggered a global health
75 crisis^{6,7}. Although it is primarily recognized for causing respiratory infections, recent studies
76 have associated COVID-19 with increased risk of stroke^{8,9,10}.

77 This association raises concerns about the mechanisms by which SARS-CoV-2 may
78 be linked to neurological damage. Hypotheses include systemic inflammation, direct invasion
79 of the nervous system by the virus, and complications of the immune response^{12,13}. In
80 addition, individuals with preexisting risk factors for stroke, such as hypertension and
81 diabetes mellitus, seem to be more likely to develop more severe cases of COVID-19 and,
82 consequently, a higher risk of stroke^{14,15,16,17,18,19}.

83 This study aims to verify the association between SARS-CoV-2 and stroke, using
84 systematic reviews as a guiding reference. The investigation seeks to contribute to the
85 scientific debate on the possible inclusion of the virus as a risk factor for cerebrovascular
86 diseases.

87 **Methodology**

88 This study is characterized as an Umbrella Review²⁰, which aims to synthesize the
89 evidence from multiple systematic reviews^{21,22}. The methodology used followed the PRIO-
90 harms²³ checklist to ensure the rigor and quality of the analysis. The formulation of the
91 research question considered the following elements: population, phenomenon of interest,
92 result, context, type of overview and general objective^{24,25,26}. Based on the hypothesis that
93 SARS-CoV-2 infection is associated with increased risk of stroke, the following guiding
94 question was formulated: "Does the association between SARS-CoV-2 and stroke presuppose
95 the need to include it as a new risk factor in the list for cerebrovascular disease?". The
96 protocol of this study was registered in the International Prospective Register of Systematic
97 Reviews, under number CRD42022323750.

98 **Search Strategy**

99 Studies published in English, Spanish, or Portuguese, from March 2020 to March
100 2023, that address the association between COVID-19 and ischemic or hemorrhagic stroke,
101 small or large vessels, in any age group, were selected. The databases consulted were
102 PubMed/MEDLINE, LILACS, Scopus, and Web of Science. The search strategy used a
103 strategic combination of terms and keywords in all three languages. The terms used were:
104 "Stroke", "COVID-19", "Neurological Complications", "Systematic review";
105 "Cerebrovascular Accident", "COVID-19", "Neurological Complications", "Systematic
106 Review"; "Stroke", "COVID-19", "Neurological Complications", "Systematic Review"

107 To complement and broaden the search, the following terms were used in different
108 combinations, using Boolean operators to improve the results: (STROKE* OR
109 CEREBROVASCULAR* OR NEUROLOGICAL*) AND (COVID* OR SARS-CoV-2*)
110 AND (SYSTEMATIC* AND REVIEW*); (("Stroke" OR "Stroke") AND ("systematic
111 review" OR "systematic review" OR "systematic review")) AND ("SARS-CoV-2").

112 **Selection criteria**

113 Scientific articles were selected that include systematic reviews, systematic reviews
114 with meta-analysis of case studies, case series, case-control studies and, preferably,
115 randomized and prospective and retrospective cohort studies. Reviews that were not available
116 in full, incomplete manuscripts, studies outside the context of systematic review, and non-
117 original research articles, such as editorial comments, opinion articles, letters, protocols,
118 reports, and book chapters, were excluded. Also excluded were reported non-clinical features,
119 such as non-neurological complications, as well as studies that presented a diagnosis of
120 COVID-19 without any reports of stroke as a complication.

121 **Data extraction**

122 The selection of articles was carried out by two independent reviewers (AMLBS and
123 EFA) in two stages. First, the titles and abstracts were independently evaluated, and any
124 disagreements were resolved by consensus. Then, the full text of the selected articles was
125 analyzed in the same way, with consensus being used to resolve disagreements.

126 The agreement between the reviewers was assessed using Cohen's Kappa coefficient²⁷.
127 In the screening phase of titles and abstracts, the Kappa coefficient was 0.62511, indicating a
128 substantial agreement among the reviewers. This result suggests that the selection criteria
129 were well defined and understood, resulting in a consistent initial selection of studies.

130 The use of the Covidence²⁸ software brought significant benefits to the review process,
131 facilitating the organization and analysis of the data, including the calculation of the Kappa
132 index and the generation of the PRISMA flowchart. This online tool allowed for real-time
133 collaboration between reviewers, simplifying the resolution of disagreements and ensuring the
134 transparency of the process.

135 **Quality assessment**

136 The methodological quality of systematic reviews was assessed using the ROBIS²⁹
137 tool, a validated and widely used instrument to assess the risk of bias in systematic reviews in
138 healthcare. The ROBIS tool is especially useful for evaluating reviews that address
139 interventions, diagnosis, prognosis, and etiology, and is therefore suitable for the scope of this
140 study.

141 The evaluation process with the ROBIS tool is divided into three main phases: Phase
142 1: Assessment of the relevance of the systematic review to the research question. In this step,

143 it is verified whether the selected systematic review directly addresses the research question
144 of the Umbrella Review.

145 Phase 2: Identification of concerns with the systematic review process. This phase
146 investigates four critical domains that may be sources of bias: Study eligibility criteria:
147 Evaluates whether the inclusion and exclusion criteria of the primary studies were adequate
148 and well-defined. Identification and selection of studies: Analyzes the search and selection
149 process of studies, checking whether there was a risk of publication bias. Data collection and
150 study evaluation: Examines the quality of data collection and the assessment of risk of bias in
151 primary studies. Synthesis and findings: Evaluates the presentation and synthesis of the
152 results, considering the heterogeneity between the studies.

153 Phase 3: Judging the overall risk of bias for the systematic review. Based on the analyses
154 of the previous phases, the overall risk of bias of the systematic review is classified as low,
155 high, or unclear.

156 **Data analysis**

157 Initially, for each identified factor, being evaluated in more than one individual study,
158 we performed a separate random-effects meta-analysis to obtain a pooled estimate of the
159 effect size, which we assumed would follow a normal distribution with variance equal to the
160 sum of the weights of the studies³⁰ (method of DerSimonian and Laird, 1986). The results of
161 the meta-analyses were the effect sizes with their corresponding 95% confidence intervals
162 (95% CI) and p-values, as well as the statistics needed to assess the level of evidence. We
163 used the effect size measure used in each original meta-analysis (i.e., RR, OR, or SMD) and
164 calculated the OR equivalents (eOR) for all effect size statistics.

165 We evaluated the heterogeneity between studies with the I^2 index³¹. I^2 values > 50%
166 indicated great heterogeneity³³. We also assessed whether there was evidence of effects from
167 small studies using the Egger test³³, where statistical significance would mean potential
168 publication bias³⁴.

169 In addition, a rating system for the strength of evidence was used, which has been
170 widely used in previous umbrella reviews^{35,36}. Specifically, we classified the levels of
171 evidence of the significant associations between each factor into convincing evidence (class
172 I), highly suggestive (class II), suggestive (class III), or weak evidence (class IV). Convincing
173 evidence would require a number ≥ 10 studies, a number of cases ≥ 500 , $I^2 \leq 50\%$, and no

174 signs of influence of small studies in the meta-analysis (Egger test ≥ 0.10). The suggestive
175 evidence required a number ≥ 10 studies, a number ≥ 400 cases, an Egger test with a p-value
176 ≥ 0.10 , and $I^2 \leq 50\%$. Weak evidence with a case count ≥ 300 , Egger's test with a P-value \geq
177 0.10 , $I^2 \leq 75\%$, and very weak evidence did not require a specific number of cases and
178 $p < 0.05$.

179 Finally, the meta-analyses were repeated estimating heterogeneity with the Hartung-
180 Knapp-Sidik-Johkman method for random effects. This method estimates variance as the
181 weighted mean square error divided by degrees freedom and assumes a distribution t^{37,38,39}.
182 The main difference between a normal distribution and a distribution t is that in the former,
183 we assume that we can know variance, while in the latter, we do not make this assumption, as
184 indeed is the case. This difference can be negligible when the number of studies is large, but it
185 can be relevant when the number of studies is small. All analyses were performed with
186 version 1.0.11 of the metaumbrella package, implemented in R environment.

187 **Results**

188 **Identification and Selection of Studies**

189 From an initial search in databases and registries, 2,490 studies relevant to the
190 investigation of the association between COVID-19 and stroke were identified. After
191 removing 1,289 duplicate references, 1,201 studies went through the screening process. Of
192 these, 141 were excluded because they did not meet the relevance criteria, focusing mainly on
193 management or medications, which was not the focus of this study. This resulted in the
194 detailed evaluation of 1,060 studies for their eligibility.

195 Of these 1,060 studies, 1,026 were excluded for various reasons, including focusing on
196 non-neurological manifestations of COVID-19, specific non-pertinent populations, medical
197 conditions unrelated to COVID-19, inadequate methodologies, or unrelated interventions.

198 At the end of this process, 34 studies were considered eligible. Of these, four studies
199 were selected for analysis in the metaumbrella, based on high methodological quality and
200 consistency with the established criteria (Figure 1).

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219


220

221

222

223

224



225 Figure 1- Prism

226 **Characteristics of the Included Studies**


227 The main characteristics of the 34 studies initially found demonstrate an important
 228 cohesion in the demographic and geographic profiles of the patients evaluated. The mean age
 229 of the patients was 61.2 years, which indicates that the study population consisted
 230 predominantly of individuals in an age group at higher risk for stroke. In addition, there was a
 231 clear predominance of males, with an average of 59.9% of participants being men. This
 232 disparity may be associated with men's greater susceptibility to developing severe forms of
 233 COVID-19 and its complications, including stroke.

234 Geographically, the studies were conducted in a variety of countries, reflecting the
 235 global spread of the pandemic. Among the most frequently cited places are the United States,
 236 Italy, India, Brazil, and Spain, with particular emphasis on China. This country has emerged
 237 as the most frequently represented location, possibly due to the initial and significant impact
 238 of the COVID-19 pandemic on its territory, which has led to increased production of data and
 239 studies on the neurological complications associated with SARS-CoV-2.

240 **Risk of Bias Assessment**

241 Figure 2 shows the evaluation of the methodological quality of the 34 studies included
 242 in the umbrella review, using the ROBIS tool. Most studies were at low risk of bias in criteria
 243 such as eligibility, identification and selection of studies, and data collection. However, some
 244 studies have shown uncertain or high risks, particularly in the selection of studies and the
 245 synthesis of results.

246 Among the four studies selected for the meta-umbrella, the assessment of bias was
 247 predominantly favorable, with all being classified as low risk in terms of overall bias.



255


256

257

258

259

260



261 Figure 2 - Quality of the ROBIS studies.

262 **Metaumbrella Results**

263 The results of the metaumbrella (Figure 3), which included four systematic reviews with
264 meta-analysis, covered a total of 70 primary studies that evaluated the association between
265 COVID-19 and stroke in five different study subjects. These objects of study were:

266 1. "COVID-19 severity and stroke risk": The meta-analysis showed that there is a significant
267 association between COVID-19 severity and increased stroke risk, with an odds ratio (eOR)
268 of 2.48 (95% CI: 1.55 – 3.95). This indicates that patients with severe COVID-19 are
269 significantly more likely to develop stroke compared to those with less severe forms of the
270 disease.


271 2. "COVID-19 and ischemic stroke risk": A significant association was found between
272 COVID-19 and a higher risk of ischemic stroke, with an eOR of 1.76 (95% CI: 1.11 – 2.80).
273 This suggests that COVID-19 infection may be a risk factor for developing ischemic stroke.

274 3. "COVID-19 and hemorrhagic stroke risk": The analysis also revealed an association
275 between COVID-19 and increased risk of hemorrhagic stroke, with an eOR of 3.86 (95% CI:
276 1.79 – 8.33). This finding indicates that, in addition to ischemic stroke, COVID-19 may also
277 be related to an increased risk of hemorrhagic stroke.

278 4. "Cerebrovascular comorbidity and mortality in patients with COVID-19": Patients with
279 cerebrovascular comorbidity who contracted COVID-19 had a higher mortality compared to
280 those who did not have a stroke, with an eOR of 2.48 (95% CI: 2.48 – 19.63). This result

281 highlights the adverse impact of pre-existing cerebrovascular conditions on the survival of
282 COVID-19 patients.

283 5. "COVID-19 and stroke mortality": Mortality was significantly higher among COVID-19
284 patients who already had a history of stroke, with an eOR of 6.08 (95% CI: 3.73 – 9.91). This
285 data underlines the severity of the impact of COVID-19 on patients who had already suffered
286 a stroke before.




292 **Figure 3.** Meta Umbrella showing the association between COVID-19 and stroke

293 In addition to these results, an overlap of two primary studies (Qureshi⁴⁰ and Merkle⁴¹)
294 was observed (Figure 4) in three distinct systematic reviews (Cui 2022⁴², Huangfu 2023⁴³,
295 and Quintanilla-Sánchez 2022)⁴⁴. The overlap of these studies in the different reviews
296 indicates that they are important and frequently cited references in the literature on the
297 relationship between COVID-19 and stroke. These findings reinforce the strong association
298 between COVID-19 infection and the risk of different types of strokes, as well as highlight
299 the higher mortality associated with stroke in patients with COVID-19.

300

| Study | Systematic Review | | | |
|-------------------|--------------------------|--------------------|-----------------------|-----------------------------------|
| | Alzoughool 2020, N=13 | Which 2022, N=4 | Huangfu 2023, N=16 | Quintanilla-Sánchez 2022, N=37 |
| Annon | - | - | + | - |
| Al-Samkari et al. | - | - | - | + |
| Benussi | - | + | - | - |
| Chen Lin | - | - | + | - |
| Chen T | + | - | - | - |
| Chen TL | + | - | - | - |

| | | | | |
|--------------------|---|---|---|---|
| Chougar et al. | - | - | - | + |
| Eric Jorge | - | - | + | - |
| Garcia-Moncó | - | - | - | + |
| Guan W | + | - | - | - |
| Guan WI | + | - | - | - |
| Guan WJ | + | - | - | - |
| Helms | - | + | - | - |
| Hu L | + | - | - | - |
| Jeffrey | - | - | + | - |
| Martí-Fábregas | - | - | + | - |
| Kimón Bekelis | - | - | + | - |
| Kremer | - | - | - | + |
| She S | + | - | - | - |
| Li, Li & Wang | - | - | - | + |
| Litton & It's Good | - | - | - | + |
| Lodigiani | - | - | - | + |
| Ludovico Ciolli | - | - | + | - |
| M Mehrpour 1 | - | - | + | - |
| Makda | - | - | - | + |
| Mandip S. Dhamoo | - | - | + | - |
| Merkler | - | + | - | + |
| Minghuan Wang | - | - | + | - |
| Naval-Baudin | - | - | + | - |
| Peterson & Brown | - | - | - | + |
| Qin C | + | - | - | - |
| Qureshi | - | + | + | - |
| Rifino | - | - | - | + |
| Rohit Bhatia | - | - | + | - |
| Romero-Sánchez | - | - | - | + |
| Seby John | - | - | + | - |
| Shadi Yagh | - | - | + | - |



301 **Figure 4.** Matrix of overlapping studies in the systematic review.

302 **Analysis of heterogeneity and bias**

303 Table 1, which presents the metaumbrella stratified by the classification of the
 304 evidence, it was observed that two of the study objects showed low heterogeneity, with I^2
 305 values below 50%. This indicates that the variability between the studies included in these
 306 study objects was relatively low, suggesting a greater consistency in the results. In particular,
 307 the "Severity of COVID-19 and stroke" and "Cerebrovascular comorbidities and mortality"
 308 demonstrated this characteristic of low heterogeneity, which strengthens confidence in the
 309 interpretation of the observed effects.

310 None of the study subjects analyzed showed the effect of small studies, as indicated by
 311 the non-significant values of the Egger test (Egger p). This suggests that the results of the
 312 meta-analyses were not significantly influenced by smaller studies, which could skew the
 313 conclusions.

314 However, two study subjects showed excess significance bias (ESB), which was
 315 identified by significant p-values: "COVID-19 and stroke mortality" ($p = 0.0252$) and
 316 "COVID-19 and risk of ischemic stroke" ($p = 0.0159$). This bias occurs when there is an
 317 excessive number of studies with positive results relative to what would be expected by the
 318 normal distribution of true effects, indicating that findings in these domains should be
 319 interpreted with caution.

320

321

322

323

324 Table 1. Total participants and P values from the Egger and JK test

| Object of study | Number of patients | Number of Cases | Number of Controls | Egger p | ESB p |
|---|--------------------|-----------------|--------------------|----------|-----------|
| COVID-19 Severity and LVCAs | 15279 | 498 | 14781 | 8.45E-01 | 5.14E-01 |
| COVID-19 and ischemic stroke risk | 36154 | 578 | 35576 | 2.84e-01 | 1.59e-02 |
| COVID-19 and hemorrhagic stroke risk | 1303 | 34 | 1269 | 1.81e-01 | 7.31e-01 |
| Cerebrovascular comorbidities and mortality | 2271 | 63 | 2208 | 8.07e-01 | 9.56e-01 |
| COVID-19 and stroke mortality | 4781 | 647 | 4134 | 1.10e-01 | 0.252e-02 |

325 Egger p = Egger's test for bias due to the influence of small studies

326 ESB p = test for bias due to Statistical Excess Significance.

327 The five study objects evaluated had a statistically significant effect size ($p < 0.05$),
328 which reinforces the validity of the findings. However, based on the criteria previously
329 established for the classification of evidence, three of these study objects were classified as
330 having weak evidence. This reflects limitations such as possible biases or inconsistencies in
331 the results, suggesting the need for further studies to confirm these associations.

332 Figure 5 complements this information by stratifying the metaumbrella by the
333 classification of evidence, visually highlighting the relative robustness of each object of study.
334 This detailed analysis allows for a more nuanced understanding of the effects of COVID-19 in
335 relation to stroke, while identifying areas where the evidence is weaker and where future
336 studies could be more informative.

337

338

339

340

341

342


343

344

345

346

347



348 **Figure 5.** Umbrella Goal stratified by Evidence Classification.

349 Discussion

350 This study started from the hypothesis that SARS-CoV-2 infection is associated with
 351 increased risk of stroke and sought to answer the guiding question: "Does the association
 352 between SARS-CoV-2 and stroke presuppose the need to include it as a new risk factor in the
 353 list for cerebrovascular disease?" since it proposes to deepen the understanding of the
 354 influence of COVID-19 on stroke risk, a global public health problem that is among the main
 355 causes of death and disability^{45,46}.

356 A point to consider is the incidence of stroke in patients with COVID-19, which is
 357 significantly higher than in patients infected with other coronaviruses, suggesting a specific
 358 pathological mechanism associated with SARS-CoV-2 that predisposes to stroke⁴⁷.

359 The meta-umbrella methodology used in this study offers significant advantages over
 360 individual systematic reviews. The comprehensive analysis of multiple meta-analyses,
 361 considering the overlap of primary studies, as exemplified by the inclusion of the study by
 362 Qureshi⁴⁰, Merkler⁴¹ in different analyses, ensures greater robustness and reliability of the
 363 results. The convergence of evidence from multiple sources, confirming the association
 364 between COVID-19 and different stroke subtypes, as well as associated mortality, strengthens
 365 the conclusion that COVID-19 represents an independent risk factor for stroke.

366 The finding of a link between COVID-19 and increased risk of stroke, especially the
 367 ischemic type, corroborates the literature that points to prothrombotic mechanisms induced by
 368 the virus^{11,12,14}. Among these mechanisms, SARS-CoV-2 infection stands out, which triggers

369 an acute inflammatory response that can result in endothelial dysfunction and a prothrombotic
370 state⁴².

371 COVID-19 is associated with a state of hypercoagulability, increasing the risk of blood
372 clots forming that can obstruct blood vessels in the brain, leading to stroke. SARS-CoV-2 can
373 directly damage endothelial cells, which line blood vessels, making them more prone to the
374 formation of these clots^{48,49}. The high incidence of thrombotic complications in patients with
375 severe COVID-19 reinforces the link between coagulation and viral infection, consolidating
376 the relevance of the findings of this study.

377 The identification of SARS-CoV-2 as a risk factor for stroke has crucial implications
378 for the prevention, diagnosis, and treatment of this condition⁵⁰. It is essential to integrate this
379 information into clinical practice, adopting measures such as: monitoring patients with
380 COVID-19 for neurological symptoms, especially those at high risk of stroke, considering
381 prophylactic anticoagulation in patients with COVID-19 and high risk of thromboembolic
382 events, implementing screening protocols for stroke in patients hospitalized with COVID-19,
383 especially in those with additional risk factors for cerebrovascular diseases⁵¹.

384 Some limitations should be considered, such as the heterogeneity in the diagnostic
385 criteria for stroke among the studies, the variability in the sample size, and the inadequate
386 control of confounding factors, such as hypertension and diabetes.

387 Future prospective, multicenter studies are essential to investigate the mechanisms
388 underlying the association between COVID-19 and stroke in greater depth, to develop
389 comprehensive clinical guidelines for the management of patients with COVID-19 and stroke
390 risk, and to evaluate the efficacy of preventive interventions, such as anticoagulation, in
391 reducing the incidence of stroke in patients with COVID-19.

392 **Conclusion**

393 The association between SARS-CoV-2 and stroke was consistent and significant,
394 suggesting that COVID-19 should be considered a new risk factor for cerebrovascular
395 diseases. However, the high heterogeneity among the studies analyzed reinforces the need for
396 further research to consolidate this relationship.

397 **Conflict of Interest Statement**

398 The author(s) declared that there are no potential conflicts of interest with respect to the
399 research, authorship and/or publication of this article.

400

401 Financing

402 The author(s) did not receive financial support for the research, authorship and/or publication
403 of this article.

404 **References**

- 405 1. World Health Organization. The top ten causes of death [Internet]. 2019 [cited 2024
406 Sep 20]. Available from: [https://www.who.int/news-room/fact-sheets/detail/the-top-](https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death)
407 [10-causes-of-death](https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death)
- 408 2. Santos D, Marques G, Almeida L, et al. Stroke as a complication of COVID-19
409 infection [Internet]. 2021 [cited 2024 Sep 20]. Available from:
410 <https://doi.org/10.51249/easn01.2021.12>
- 411 3. Sirisha S, et al. Conscientização, reconhecimento e resposta ao AVC entre o público
412 em geral – um estudo observacional. J Neurosci Rural Pract. 2021;12(4):704.
413 doi: [10.1055/s-0041-1735822](https://doi.org/10.1055/s-0041-1735822)
- 414 4. Cui Q, Naikoo NA. Modifiable and non-modifiable risk factors in ischemic stroke: a
415 meta-analysis. Afr Health Sci. 2019 Jun;19(2):2121-9. DOI: [10.4314/ahs.v19i2.36](https://doi.org/10.4314/ahs.v19i2.36).
416 PMID: 31656496; PMCID: PMC6794552.
- 417 5. Choudhury MS, Chowdhury Md, Nayeem A, et al. Modifiable and Non-Modifiable
418 Risk Factors of Stroke: A Review Update. J Natl Inst Neurosci Bangladesh. 2015;
419 1:22. [https://doi: 10.3329/jninb.v1i1.22944](https://doi.org/10.3329/jninb.v1i1.22944).
- 420 6. Zhou P, et al. A pneumonia outbreak associated with a new coronavirus of probable
421 bat origin. Nature. 2020. Available from: <https://doi.org/10.1038/s41586-020-2012-7>
- 422 7. Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus – the species
423 and its viruses, a statement of the Coronavirus Study Group. bioRxiv. 2020. Available
424 from: <https://doi.org/10.1101/2020.02.07.93786>
- 425 8. Zhu N, et al. A novel coronavirus of pneumonia patients in China, 2019. N Engl J
426 Med. 2020; 382:727-33. <https://doi.org/10.1056/nejmoa2001017>
- 427 9. Qi X, Keith KA, Huang JH. COVID-19 and stroke: A review. Brain Hemorrhages.
428 2021 Jun;2(2):76-83. doi: 10.1016/j.hest.2020.11.001. Epub 2020 Nov 17. PMID:
429 33225251; PMCID: PMC7670261.
- 430 10. Bass DI, Meyer RM, Barros G, et al. The impact of the COVID-19 pandemic on
431 cerebrovascular disease. Semin Vasc Surg. 2021 Jun;34(2):20-7. doi:
432 [10.1053/j.semvascsurg.2021.05.001](https://doi.org/10.1053/j.semvascsurg.2021.05.001). Epub 2021 May 20. PMID: 34144743; PMCID:
433 PMC8136291.

- 434 11. Lashkari A, Ranjbar R. A case-based systematic review on the SARS-COVID-2-
435 associated cerebrovascular diseases and the possible virus routes of entry. J
436 Neurovirol. 2021 Oct;27(5):691-701. doi: 10.1007/s13365-021-01013-8. Epub 2021
437 Sep 21. PMID: 34546547.
- 438 12. Stein LK, Mayman NA, Dhamoon MS, et al. The emerging association between
439 COVID-19 and acute stroke. Trends Neurosci. 2021;44(7):527-37. Available from:
440 <https://doi.org/10.1016/j.tins.2021.03.005>
- 441 13. Tsivgoulis G. Epidemiology of ischemic stroke during the COVID-19 pandemic:
442 navigating uncharted waters with tidal changes. Stroke. 2020; 51:1924-6.
443 <https://doi.org/10.1161/strokeaha.120.030791>
- 444 14. Vogrig A, Bagatto D, Gigli GL, et al. Causality in COVID-19-associated stroke: a
445 uniform case definition for use in clinical research. J Neurol. 2021;268(3):758-61.
446 Available from: <https://doi.org/10.1007/s00415-020-10103-2>
- 447 15. John S, Kesav P, Mifsud VA, et al. Characteristics of Large-Vessel Occlusion
448 Associated with COVID-19 and Ischemic Stroke. AJNR Am J Neuroradiol. 2020
449 Dec;41(12):2263-8. doi: 10.3174/ajnr.A6799. Epub 2020 Aug 27. PMID: 32855182;
450 PMCID: PMC7963240.
- 451 16. Jillella DV, Janocko NJ, Nahab F, et al. Ischemic stroke in COVID-19: An urgent need
452 for early identification and management. PLoS One. 2020;15(9).
453 <https://doi.org/10.1371/journal.pone.0239443>
- 454 17. Belani P, Schefflein J, Kihira S, et al. COVID-19 is an independent risk factor for
455 acute ischemic stroke. Am J Neuroradiol. 2020;41(8):1361-4.
456 <https://doi.org/10.3174/ajnr.a6650>
- 457 18. Lee KW, Yusof Khan A, Ching SM, et al. Stroke and novel coronavirus infection in
458 humans: A systematic review and meta-analysis. Front Neurol. 2020;11.
459 <https://doi.org/10.3389/fneur.2020.579070>
- 460 19. Avula A, Nalleballe K, Narula N, et al. COVID-19 presenting as stroke. Brain Behav
461 Immun. 2020; 87:115-9. <https://doi.org/10.1016/j.bbi.2020.04.077>
- 462 20. Pollock M, Fernandes RM, Becker LA, et al. Overview of revisions. Cochrane Handb
463 Rev Interv Syst Version. 2018;6. Available from:
464 <https://training.cochrane.org/handbook/current/chapter-v>
- 465 21. Smith V, Devane D, Begley CM, et al. Methodology in conducting a systematic
466 review of systematic reviews of health interventions. BMC Med Res Methodol.
467 2011;11(1):15.
- 468 22. Aromataris E, Fernandez R, Godfrey CM, et al. Summarizing systematic reviews:
469 methodological development, conduct and reporting of an umbrella review approach.
470 Int J Evid Based Healthc. 2015 Sep;13(3):132-40. doi:
471 10.1097/XEB.0000000000000055. PMID: 26360830.

- 472 23. Donato H, Donato M. Revisão de revisões: Guia passo a passo. Porto Acta Med
473 [Internet]. 2024 Jul 1 [cited 2024 Sep 20];37(7-8):547-55. Available from:
474 <https://actamed.com/re/indice.php/amp/artigo/visualizar/21796>
- 475 24. Hunt H, Pollock A, Campbell P, et al. An introduction to reviews overviews: planning
476 a relevant and objective research question for an overview. Syst Rev. 2018; 7:39.
477 Available from: <https://doi.org/10.1186/s13643-018-0695-8>
- 478 25. Becker LA, Oxman AD. Chapter 22: Overview of Revisions. In: Higgins JPT, Green
479 S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0
480 [updated 2011 Mar]. The Cochrane Collaboration; 2011 [cited 2024 Sep 20]. Available
481 from: <http://training.cochrane.org/handbook>
- 482 26. Deeks JJ, Bossuyt PM, Gatsonis C, editors. Cochrane Handbook for Systematic
483 Reviews of Diagnostic Test Accuracy. Version 0.9. The Cochrane Collaboration; 2013.
484 Available from: <http://methods.cochrane.org/sdt/handbook-dta-reviews>
- 485 27. Oliveira NS, Oliveira JM, Bergamaschi DP. Inter-raters' agreement in the selection of
486 articles in systematic reviews. Rev Bras Epidemiol. 2006; 9:309-15.
- 487 28. Covidence systematic review software. Veritas Health Innovation, Melbourne,
488 Australia. Available from: www.covidence.org
- 489 29. Whiting P, et al. ROBIS: a new tool to assess the risk of bias in systematic reviews has
490 been developed. J Clin Epidemiol. 2016;69. <https://doi.org/10.1016/j.jclinepi.2015.06.005>
- 491 30. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;
492 7:177-88. Available from: [https://doi.org/10.1016/0197-2456\(86\)90046-2](https://doi.org/10.1016/0197-2456(86)90046-2)
- 493 31. Ioannidis JPA, Trikalinos TA. An exploratory test for an excess of significant findings.
494 Clin Trials. 2007; 4:245-53. Available from:
495 <https://doi.org/10.1177/1740774507079441>
- 496 32. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions.
497 Version 5.1.0. Cochrane Handbook for Systematic Reviews of Interventions. Version
498 5.1.0. <https://handbook-5-1.cochrane.org/>
- 499 33. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a
500 simple, graphical test. BMJ. 1997; 315:629-34. Available from:
501 <https://doi.org/10.1136/bmj.316.7129.469>
- 502 34. Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and
503 interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.
504 BMJ. 2011;343. Available from: <https://doi.org/10.1136/bmj.d4002>
- 505 35. Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. Evid Based
506 Ment Health. 2018; 21:95-100. Available from: [https://doi.org/10.1136/ebmental-
507 2018-300014](https://doi.org/10.1136/ebmental-2018-300014)

- 508 36. Ioannidis JPA. Integration of evidence from multiple meta-analyses: a primer on
509 umbrella reviews, treatment networks and multiple treatments meta-analyses. *CMAJ*.
510 2009; 181:488-93. Available from: <https://doi.org/10.1503/cmaj.081086>
- 511 37. Hartung J. An alternative method for meta-analysis. *Biom J*. 1999;901-16.
- 512 38. IntHout J, Ioannidis JP, Borm GF. Obtaining evidence by a single well-powered trial
513 or several modestly powered trials. *Stat Methods Med Res*. 2016;25(2):538-52.
- 514 39. Sidik K, Jonkman JN. Robust variance estimation for random-effects meta-analysis.
515 *Comput Stat Data Anal*. 2006;50(12):3681-701. doi: 10.1016/j.csda.2005.07.019
- 516 40. Qureshi AI, Baskett WI, Huang W, et al. Acute ischemic stroke and COVID-19: an
517 analysis of 27 676 patients. *Stroke*. 2021;52(3):905-12.
518 <https://doi.org/10.1161/strokeaha.120.031786>
- 519 41. Alzoughool F, Alanagreh L, Abumweis S, et al. Cerebrovascular comorbidity, high
520 blood levels of C-reactive protein and D-dimer are associated with disease outcomes
521 in COVID-19 patients. *Clin Hemorheol Microcirc*. 2021;77(3):311-22.
522 <https://doi.org/10.3233/ch-201002>. PMID: 33185593.
- 523 42. Cui Y, Zhao B, Li T, et al. Risk of ischemic stroke in patients with COVID-19
524 infection: a systematic review and meta-analysis. *Brain Res Bull*. 2022 Mar; 180:31-7.
525 doi: 10.1016/j.brainresbull.2021.12.011. Epub 2021 Dec 31. PMID: 34979237;
526 PMCID: PMC8719366.
- 527 43. Huangfu X, Li X, Chen M, et al. A meta-analysis of the impact of COVID-19 on
528 stroke mortality. *Chin Gen Pract*. 2023;26(3):348. [https://doi.org/10.12114/j.issn.1007-](https://doi.org/10.12114/j.issn.1007-9572.2022.0480)
529 [9572.2022.0480](https://doi.org/10.12114/j.issn.1007-9572.2022.0480)
- 530 44. Quintanilla-Sánchez C, Salcido-Montenegro A, González-González JG, et al. Acute
531 cerebrovascular events in severe and non-severe COVID-19 patients: a systematic
532 review and meta-analysis. *Rev Neurosci*. 2022 Feb 10;33(6):631-9. doi:
533 10.1515/revneuro-2021-0130. PMID: 35142148.
- 534 45. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19.
535 *Lancet Neurol*. 2020;19(9):767-83. [https://doi.org/10.1016/s1474-4422\(20\)30221-0](https://doi.org/10.1016/s1474-4422(20)30221-0)
- 536 46. Collaborators GBD, et al. Global, regional, and national burden of stroke and its risk
537 factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study
538 2019. *Lancet Neurol*. 2021;20(10):795-820. [https://doi.org/10.1016/s1474-](https://doi.org/10.1016/s1474-4422(21)00252-0)
539 [4422\(21\)00252-0](https://doi.org/10.1016/s1474-4422(21)00252-0)
- 540 47. Nannoni S, de Groot R, Bell S, et al. Stroke in COVID-19: a systematic review and
541 meta-analysis. *J Stroke*. 2021;16(2):137-49. doi: 10.1177/1747493020972922.
- 542 48. Klok FA, Kruip MJ, van der Meer NJ, et al. Incidence of thrombotic complications in
543 critically ill ICU patients with COVID-19. *Thromb Res*. 2020 Jul; 191:145-7. doi:

544 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10. PMID: 32291094; PMCID:
545 PMC7146714.

546 49. Oliveira LMDM, Nascimento NSD, Pereira ABCNDG. COVID-19 and the incidence
547 of ischemic stroke after infection: an integrative literature review. Rev Bras Neurol
548 (Online). 2024;5-10. <https://doi.org/10.46979/rbn.v60i1.64134>

549 50. Paniz-Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system involvement by
550 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020.
551 Available from: <https://doi.org/10.1002/jmv.25915>.

552 51. Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risk of acute myocardial
553 infarction and ischemic stroke following COVID-19 in Sweden: a self-controlled case
554 series and matched cohort study. Lancet. 2021;398(10300):599-607.
555 [https://doi.org/10.1016/s0140-6736\(21\)00896-5](https://doi.org/10.1016/s0140-6736(21)00896-5)

556

557

558 All worksheets can be provided by the corresponding author through the email
559 request andrezamlb@gmail.com

560